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Berlin, Germany
Peripheral arterial disease (PAD) is a highly prevalent atherosclerotic syndrome associated with significant morbidity and
mortality. PAD is most commonly caused by atherosclerosis obliterans (ASO) and thromboangiitis obliterans (TAO),
and can lead to claudication and critical limb ischemia (CLI), often resulting in a need for major amputation and
subsequent death. Standard treatment for such severe cases of PAD is surgical or endovascular revascularization.
However, up to 30% of patients are not candidates for such interventions, due to high operative risk or unfavorable
vascular involvement. Therefore, new strategies are needed to offer these patients a viable therapeutic option. Bone-
marrow derived stem and progenitor cells have been identified as a potential new therapeutic option to induce
angiogenesis. These findings prompted clinical researchers to explore the feasibility of cell therapies in patients with
peripheral and coronary artery disease in several small trials. Clinical benefits were reported from these trials including
improvement of ankle-brachial index (ABI), transcutaneous partial pressure of oxygen (TcO2), reduction of pain, and
decreased need for amputation. Nonetheless, large randomized, placebo-controlled, double-blind studies are necessary
and currently ongoing to provide stronger safety and efficacy data on cell therapy. Current literature is supportive of
intramuscular bone marrow cell administration as a relatively safe, feasible, and possibly effective therapy for patients
with PAD who are not subjects for conventional revascularization. (J Vasc Surg 2011;53:445-53.)
Clinical Relevance: This article describes the background and first results of stem and progenitor cell therapy in patients
with critical limb ischemia not suitable for revascularization. The principle as far as it is understood and the methods are
described. Compelling evidence suggests that progenitor cell therapy might become a useful adjunct to the treatment
options at present. Due to poor prognosis and the increasing number of patients, there is a need for new therapeutic
methods. The article gives an overview of first encouraging results provided by early-phase clinical trials. Challenges in
this new therapeutic option still include open questions such as cell phenotype, processing, dosing, route of optimal
delivery, and frequency of application. Validation by more rigorous controlled trials involving homogenous patient
populations are required to confirm the first hopeful results.
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cPeripheral artery disease (PAD) is a highly prevalent
atherosclerotic syndrome that affects approximately 8 to 12
million individuals in the United States and is associated
with significant morbidity and mortality.1 An additional
cause of PAD is Buerger disease, also called thromboangi-
itis obliterans (TAO), which is a nonatherosclerotic, seg-
mental inflammatory disease most frequently affecting the
small and medium-sized arteries and veins in the upper and
lower extremities and is strongly associated with heavy
tobacco use.2 Risk factors for atherosclerotic PAD are
mainly, but not exclusively, smoking and diabetes, and are,
therefore, identical with those for atherosclerosis in the
cerebrovascular and coronary circulation. Comorbid PAD
substantially increases the mortality risk conferred by coro-
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ritical limb ischemia (CLI) is the endstage of lower ex-
remity PAD in which severe obstruction of blood flow
esults in ischemic rest pain, ulcers, and a significant risk for
imb loss. CLI is not a specific disease per se, rather, it
epresents a syndrome that may develop from many funda-
entally distinct pathophysiological processes. For all
tages of the disease, minimization of risk factors is manda-
ory. The mainstay of therapy for severe, limb-threatening
schemia is either surgical or endovascular revascularization
iming to improve blood flow to the affected extremity.
pproximately 20% to 30% of patients with CLI are not
onsidered candidates for vascular or endovascular proce-
ures, however, with amputation often being the only
ption. This corresponds to about 100,000 major leg
mputations in the EuropeanUnion, and to 120,000 in the
nited States.4 Leg amputation due to atherosclerotic
AD gives rise to an acute mortality rate of around 30% and
5-year prognosis with survival rates of less than 30%.5,6
lbeit life expectancy is not as severely limited for patients
uffering from Buerger disease or TAO, major amputations
ecessary for these individuals often result in severe handi-
aps in the usually younger patients.
To alleviate symptoms of PAD, research has been fo-
using on the use of bone marrow (BM)-derived stem and
rogenitor cells, which were identified as a potential new
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February 2011446 Lawall et altherapeutic option to induce therapeutic angiogenesis. The
goal was to improve the vascularization of the ischemic leg
so that perfusion increases sufficiently for wound healing to
occur, and to resolve pain at rest, this ultimately allowed
limb salvage for these patients.
Angiogenesis and arteriogenesis. In patients with
obstructive artery disease, two different forms of compen-
satory vessel growth occur, angiogenesis and arteriogen-
esis. Angiogenesis is the formation of a capillary network,
through the activation and proliferation of endothelial cells
in ischemic tissue. Therefore, it is also often called capillary
growth. It occurs as a sprouting of small endothelial tubes
from pre-existing capillary beds in response to local hyp-
oxia. It is mediated by hypoxia-induced release of cytokines
(vascular endothelial growth factor [VEGF] and related
growth factors). No influx of non-tissue resident cells is
needed.7 The resulting capillaries are small, with a diameter
of about 10 to 20m, and cannot sufficiently compensate/
substitute for a large occluded transport artery due to
Hagen-Poiseuille law (Fig 1).
Arteriogenesis, also called collateral growth, is the
transformation of pre-existent collateral arterioles into
functional collateral arteries, meaning an increase in the
diameter of existing arterial vessels capable of compensating
for the loss of function of occluded arteries.8 The original
diameter of a small, initially non-perfused arteriole may
increase up to 20 times during the process of arteriogen-
esis.9,10 It is initiated when shear stresses increase in the
pre-existent collateral pathways upon narrowing of a main
Fig 1. Schematic diagram of putative events in the angio
permission from Lawall et al.4)artery. The increased shear stress leads to an upregulation of gell adhesion molecules for circulating monocytes, which
ubsequently accumulate around the proliferating arteries
nd provide the required cytokines and growth factors.11
xperimental evidence in animal models of limb ischemia
ndicates that endogenous arteriogenesis can almost fully
estore a normal vascular conductance induced by large
essel occlusion. This correlates well with the clinical ob-
ervation that many patients with PAD and, for example,
emoral artery occlusion are free of ischemic symptoms
ecause their collateral network delivers enough blood to
eet the perfusion need of the lower limb.12 The following
verview will describe the physiology of arteriogenesis.
Physiology of collateral artery growth (arteriogen-
sis). Mechanically, arteriogenesis is linked to elevated
ressure, which increases radial wall stress, and elevated
ow thus increasing endothelial surface stress. The vessel
ncreases in diameter until the stress is normalized. The
ctivation of the collateral endothelium caused by increased
uid shear stress is reflected by the upregulation of adhe-
ion molecules and by the release of cytokines that attract
irculating monocytes. These adhere and invade the collat-
ral vessel wall. Increase of T cell numbers and granulocytes
as also been reported in addition to this monocyte/
acrophage accumulation around growing collaterals, em-
hasizing the importance of circulating cells to this type
f vascular growth.13 The invading monocytes are BM-
erived cells with monocytic and/or macrophagic surface
arkers. Matrix proteases are hereby activated in the peri-
ollateral space and destruct the tissue surrounding the
c process. EC, Endothelial cell. (Figure reproduced withgenirowing vessel, producing a space into which the collateral
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Volume 53, Number 2 Lawall et al 447arterial wall can expand (Fig 2). These physiologically
preformed arterio-arterial collateral connections increase in
size and diameter in a temporally and spatially well-defined
cascade of events until a working three-layered collateral
artery restores blood flow 4 to 6weeks after initial occlusion
of the large artery.14 The question remains, however,
whether these effects can be attributed to the incorporation
of stem cells into the wall of the new vessel, or to the
cytokines released by chemo-attracted BM cells inducing
proliferation of resident endothelial cells. Findings by Kin-
naird et al15 suggest that cultured human BM-derived
stromal cells promote arteriogenesis through paracrine
mechanisms. This notion is supported by Heil et al,13 who
suggest that in the adult organism, bone marrow cells
(BMCs) do not promote vascular growth by incorporating
into vessel walls but rather act as “cytokine factories,”
promoting vascular growth by paracrine effects. Findings
by Jin et al16 also support this concept by which ischemia
induces plasma elevation of stem and progenitor cell-active
cytokines, including sKitL (Soluble Kit-ligand) and throm-
bopoietin, and, to a lesser extent, progenitor-active cyto-
kines, such as granulocyte-macrophage colony-stimulating
factor (GM-CSF) and erythropoietin. Thrombopoietin and
sKitL induced the release of stromal-derived factor-1
(SDF-1) from platelets, thereby increasing systemic plasma
levels of SDF-1 (stromal-derived factor-1 also known as
CXCL12). This results in a substantial mobilization of
CXCR4VEGFR1 cells, accelerating revascularization
of the ischemic limbs. Jin et al16 term this unique class of
CXCR4VEGFR1 cells “hemangiocytes,” which repre-
sent a heterogeneous population of VEGF-responsive non-
endothelial, proangiogenic hematopoietic progenitors
consisting of immature and differentiated myelomonocytic
Fig 2. Schematic diagram of putative events in the arteriogenic
process. EC, Endothelial cell; GM-CSF, granulocyte-macrophage
colony-stimulating factor; MCP-1, monocyte chemoattractant
protein-1; PDGF, platelet derived growth factor; SMC, smooth
muscle cell; TNF-, tumor necrosis factor-. (Figure reproduced
with permission from Lawall et al.4)cells. Hemangiocytes also express progenitor markers and induce neovascularization by releasing angiogenic factors
nd by physically supporting the assembly of endothelial
ells.
Nonetheless, this regenerative repair mechanism of ar-
eriogenesis by recruitment of monocytic BM cells fails to
ork adequately in a large number of patients, resulting in
dvanced peripheral ischemia and, ultimately, in limb loss.
he so-called “circulating endothelial progenitor cells”
EPCs), originally identified by Asahara et al17 in a mouse
odel, were also recently found to originate from the
onocyte-macrophage lineage, thus being likely to be
dentical to the BM-derived monocytic cells active in the
erivascular collateral artery space.18
Interestingly, the risk factors observed for advanced
schemia due to insufficient collateralization (diabetes,
moking, hyperlipidemia, and advanced age) are the same
or a lower number of circulating, monocytic EPCs.19-23
his observation strengthens the pivotal position of BM-
erived monocytes in PAD repair, enabling imitation and
oosting of physiological repair processes to ultimately
nduce arteriogenesis.
Animal models of cell therapy in limb ischemia. Pu-
ative endothelial cell (EC) progenitors which subsequently
ifferentiated to ECs in vitro were first isolated by Asahara
t al17 from human peripheral blood, using separation
ethods based on cell surface antigen expression. These
eterologous, homologous, and autologous EC progeni-
ors were then found to incorporate into sites of active
ngiogenesis in animal models of ischemia. These findings
uggested that EC progenitors could augment collateral
essel growth to ischemic tissues (therapeutic angiogenesis)
nd deliver anti-angiogenic or pro-angiogenic agents, re-
pectively, to sites of pathologic or utilitarian angiogenesis.
ince then, stem cell therapy has been used in a large
umber of rat, rabbit, and mouse models to improve limb
ascularity. These experiments demonstrated that the num-
er of circulating EPCs increase in response to ischemia,
nd those cells were incorporated into capillaries and inter-
titial arteries.24,25 The caveat of these studies was that hind
imb ischemia was induced in models of acute, but not of
hronic ischemia by unilateral ligation or coagulation of the
ommon femoral artery.15,26-29 The need for specific ani-
al models with true degenerative arteriosclerotic disease
herefore remains, as the latter is the most frequent etiology
f human PAD. Notwithstanding, encouraging results of
reclinical studies have rapidly led to several small clinical
rials in which BM-derived mononuclear cells were also
dministered to patients with limb ischemia caused by
therosclerotic PAD. In the following, we will attempt to
ive an overview of clinical trials for the use of autologous
ell therapy for patients with PAD.
Autologous stem cell therapy trials. The preclinical
tudies establishing that BM-derived mononuclear cells
BM-MNC), including EPCs, into ischemic limbs increase
ollateral vessel formation prompted clinical researchers to
xplore the feasibility of cell therapies in patients with PAD.
he first large report on the use of BM-MNC in limb
schemia was the Therapeutic Angiogenesis by Cell Trans-
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February 2011448 Lawall et alplantation (TACT) study by Tateishi-Yuyama et al.30 The
protocol consisted of an open pilot study in which efficacy
and safety of autologous implantation of BM-MNC was
established, and a randomized controlled confirmatory
part, comparing the efficacy of BM-MNC vs peripheral
blood (PB)-MNC treatment. In the latter part, patients
(n 22) with bilateral leg ischemia were randomly injected
with BM-MNC in one leg (active treatment), or with
PB-MNC into the other as a control. At 4 weeks, ankle-
brachial index (ABI) was significantly improved in legs
injected with BM-MNC compared with those injected with
PB-MNC (difference 0.09 [95% confidence interval {CI},
0.06–0.11]; P  .0001). Similar improvements were seen
for transcutaneous oxygen pressure (TcO2; 13 [95% CI,
9–17]; P  .0001), rest pain (0.85 [95% CI, 1.6 to
0.12]; P  .025), and pain-free walking time (1.2 [95%
CI, 0.7–1.7]; P  .0001). Legs injected with PB-MNC
cells showed much smaller increases of ABI and TcO2. The
improvements in the BM-MNC-injected legs were sus-
tained at 24 weeks.30 The authors concluded that the
higher efficacy of implantation of BM-MNCs as compared
to PB-MNCs was due to the supply of endothelial progen-
itor cells (included in the CD34 fraction), and multiple
angiogenic factors (released from the CD34 fraction).
The publication of TACT and the first studies on
cardiac stem cell therapy31 raised general interest in stem
cell treatment for vasculogenesis, and lead to the use of
stem cell/BM-MNC therapy for peripheral ischemia in a
number of different countries. An overview of these studies
has been recently published by Lawall et al.4 Despite the
limitations presented by not only the variable methods of
cell isolation, but also by the variable degrees of ischemia
and often small number of study subjects, the outcome of
the listed BM-derived cell therapy on perfusion parameters
(ABI, TcO2) and clinical course (wound healing, walking
distance) was remarkably consistent and positive through-
out the different reports. Pooled results show that autolo-
gous cell therapy induces ABI increases between 0.1 and
0.2 points, and TcPO2 increases of 10 to 20 mm Hg O2.
Depending on baseline values, walking distance was shown
to improve to a mean of 100 to 200 meters. In addition, no
serious side effects were reported.
A recent meta-analysis by Fadini et al32 searching for
effective autologous cell therapy studies for the treatment
of PAD yielded 108 studies, 42 of which were clinical trials
and 37 of which were potentially appropriate to be meta-
analyzed. From these 37 trials in which autologous cell
therapy was effective in improving surrogate indexes of
ischemia, subjective symptoms, and hard end points (ulcer
healing and amputation), 24 had usable data for ABI
measurements, 13 had usable data for TcO2, 20 had usable
data for pain, and 11 had usable data for walking distance.
Considering all trials of cell therapy, ABI improved
from 0.46  0.04 before therapy to 0.63  0.04 after
therapy (P  .011), whereas ABI improved by 0.115 
0.060 (P  .054) when considering only controlled trials.
In trials with granulocyte-colony stimulating factor (G-
CSF) monotherapy, ABI was not significantly increased, sonsidering all studies (from 0.41  0.09 to 0.59  0.11;
 .30) and controlled studies only (difference 0.049 
.22; P .83). TcO2 increased from 22.8 2.8 to 35.8
.9 (P  .0002) considering all trials of cell therapy, and
ncreased by 12.8  7.0 (P  .069) considering only
ontrolled trials. Data on TcO2 in trials with G-CSFmono-
herapy were too limited to be analyzed. Walking capacity
ncreased significantly considering all trials (from 75.7 
9.4 to 402.3  70.9 meters; P  .0001), but was com-
rehensively reported in only one G-CSF therapy trial with
o significant difference vs placebo. Pain (on a 0-10 scale)
as also found to be significantly reduced in cell therapy
rials, regardless of whether all trials (6.35 0.43 to 2.11
.37; P  .0001) or controlled trials only (2.39  1.01;
 .019) were considered. In G-CSF trials, pain was not
ignificantly reduced. Ulcer healing significantly improved
n the active treatment group vs the control group (odds
atio [OR], 3.54, 95% CI, 1.09–11.51; P  .032) in
ontrolled cell therapy trials. This was not the case for the
ne reported trial of G-CSF therapy. Amputation as an
utcome was explored in only two controlled trials of cell
herapy part of the Fadini et al32 meta-analysis, indicating a
ignificant benefit in terms of limb salvage as compared to
ontrol treatment (OR for amputation 0.09; 95%CI, 0.02–
.44; P  .0005). No assessment of incidences of amputa-
ion was done in controlled G-CSF trials. The overall
onclusion of the Fadini et al32 meta-analysis is that cell
herapy is able to significantly improve ABI, TcO2, rest
ain, pain-free walking distance, ulcer healing, and limb
alvage. In contrast, G-CSF monotherapy was not associ-
ted with significant improvement of these end points,
lbeit final conclusions should be deferred because the
umber of G-CSF testing trials was limited (Fadini et al32
nd references therein).
Importance of cell type and origin. The concept of
herapeutic angiogenesis was driven by the theoretical con-
ept that BM-derived EPCs could incorporate into dam-
ged vessel endothelium and promote collateral vessel for-
ation. However, albeit being a promising tool for cell
herapy, a clear and physiologically relevant definition of
PCs still remains elusive. Co-recruitment of angiocompe-
ent hematopoietic cells delivering specific angiogenic fac-
ors facilitate incorporation of EPCs into newly sprouting
lood vessels. It seems that cell therapy for treatment of
AD using either whole BM-MNCs or G-CSF-mobilized
hole PB-MNCs is more successful than use of subfrac-
ionated cell preparations (eg, CD 133 or highly purified
D 34 cells) from peripheral blood after G-CSF mobili-
ation.33,34 Several studies with growth factor liberated
B-MNC were performed with results very similar to those
f BM-MNC trials, which were lately reviewed by Lawall et
l.4 The question of whether G-CSF mobilized PB-MNCs
r BM-MNCc achieved better primary outcomes with re-
pect to safety and efficacy of treatment, improved ABI and
est pain were directly addressed in a study byHuang et al35
or patients with lower limb TAO. Significant improvement
f the above outcomes was observed in both groups of the
tudy (group A receiving G-CSF mobilized PB-MNCs,
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Volume 53, Number 2 Lawall et al 449group B receiving BM-MNCs) after transplantation. Com-
parative analysis revealed that at 12 weeks after cell implan-
tation, improvement of ABI (difference 0.06  0.01; P 
.0001), skin temperature (difference 0.55  0.25; P 
.028), and rest pain (difference 0.57  0.15; P 
.0001) was significantly better for patients in group A
(G-CSF mobilized PB-MNCs) than for those in group B
(BM-MNCs). However, there was no significant difference
between the two groups for pain-free walking distance,
TcO2, ulcers, and rate of lower limb amputation.
35
The meta-analysis by Fadini et al,32 which included
trials for the treatment of PAD, CLI, TAO, atherosclerosis
obliterans (ASO), and peripheral vascular disease, reports
mobilized PB-MNC therapy to be consistently associated
with slight but not significantly better improvements in
ABI, TcO2 and pain-free walking distance for all trials than
BM-MNC therapy. Pain-scale reduction was significantly
better with mobilized PB-MNCs than with BM-MNCs
(P  .006). However, BM-cell therapy significantly im-
proved a hard end point such as ulcer healing (OR 7.23; P
 .038), whereas mobilized PB-MNCs did not (OR 2.24;
P  .13). There were no significant differences in the
clinical characteristic between patients treated with mobi-
lized PB-MNCs or BM cells. As stated above, Fadini et al32
found that G-CSF monotherapy led to nonsignificant im-
provement in ABI, pain-free walking distance, rest pain, and
ulcer healing, this observation being in compliance with the
results of a double-blinded randomized, placebo-controlled
study showing no superiority of G-CSF over placebo.36
With respect to different surface phenotypes of BM-
MNCs and PB-MNCs, Romagnani et al37 were able to
demonstrate that PB-MNC-derived EPCs seem to be
CD14 by using the conventional cytofluorometric
technique; however, virtually all cells were also found to
express low levels of surface CD34 when assessed by the
highly sensitive antibody conjugated magnetofluores-
cent liposomes (AC-MFL) or fluorescence amplification
by sequential employment of reagents (FASER). These
CD14CD34low cells represented a variable proportion
at individual levels of CD14 cells, and constituted the
dominant population among circulating KDR cells,
indicating that the major source of EPCs obtainable
from PB is a subset of double-positive CD14CD34low
cells showing phenotypic and functional features of mul-
tipotent stem cells.37 In addition, Peichev et al38 found
that AC133, an early hematopoietic stem cell marker, is
expressed on a large subset of circulating endothelial
precursors but not on the mature endothelium. The
percentage of CD34 cells expressing AC133 and
VEFGR2 cells is only 2% of circulating CD3 cells.
This figure is much less than the percentage of CED34
VEGFR-2 cells previously reported by other groups.
It should also be remembered that autologous BM or
autologous peripheral-blood cells were used in all of the
above-mentioned studies. Therapies with allogenous cells
from another donor or pooled from several donors as in a
placental cell concentrate are solely in animal-trials or phase
I trials with no publications on their effect in humans so far. sIntramuscular vs intra-arterial administration. In-
ramuscular and intra-arterial injection or a combination of
oth has yielded promising results in the treatment of
uman PAD. The underlying principle of intramuscular
njection is the creation of a cell depot with paracrine
ctivity in the ischemic area. However, the mechanisms by
hich transplanted cells improve the patients’ clinical status
re thus far unclear. Experimental animal studies indicate
hat BM-derived cells contribute to vascular and muscle
egeneration by physically integrating into the tissue
nd/or by secreting growth factors.13,39
Intramuscular injection was usually performed into the
astrocnemius muscle along a symmetric grid with a fixed
umber of injections (between 20 and 60) in most human
rials (Lawall et al4). In the recent pilot, BM outcomes
rial 1 (BONMOT-1)40 and in the follow-up placebo-
ontrolled double blind study (BONMOT-CLI),41 injec-
ions were placed along the occluded native arteries, be-
ause the density of preformed collaterals is highest in
arallel orientation to the axial arteries, and this is the
referred location for collateral growth. In BONMOT 1
nd 2, the number of injections was increased correspond-
ng to the length of the arterial occlusion, from 40 injec-
ions for infrapopliteal disease only, to 60 injections if
emoral, popliteal, and infrapopliteal disease was present.
owever, no direct comparisons between different intra-
uscular injection sites and numbers exist. In the meta-
nalysis by Fadini et al,32 the most common route of cell
dministration was intramuscular (33 trials). Only four
rials used intra-arterial route of administration, one trial
ombined intra-arterial plus intramuscular routes, and one
rial compared intramuscular vs intramuscular plus intra-
rterial cell administration. ABI and TcO2 were found to be
ignificantly improved only after intramuscular, and not
fter intra-arterial cell therapy. However, both significantly
nd comparably improved pain and pain-free walking dis-
ance. Intramuscular cell therapy significantly improved
lcer healing (OR 2.62; P  .029), whereas this could not
e assessed in the details in trials of intra-arterial cell ther-
py.32
Isolation and dosage of stem cells for therapeutic
asculogenesis. It is necessary to isolate and concentrate
onocytic precursor cells. Improvements of current cell
herapy aim at establishing effective and straightforward
pplication methods that can be performed easily and in a
imely fashion. This sounds self-evident; however, the
ometimes complex requirements for cell isolation proce-
ures have been obstacles for the wider application of cell
herapy in PAD.
Most studies used between 100 to 800 mL of BM
lood as a mean extraction volume. The mononuclear cell
raction was enriched by different separation techniques:
1) by Ficoll density gradient system centrifugation and
ariations thereof42-45; (2) by use of blood centrifugation
nd plasmapheresis systems (ie, COBE Spectra, Gambro,
weden; CS 3000-Plus, Baxter Healthcare, Deerfield,
ll)30; or (3) by use of point-of-care, bedside centrifugation
ystems (SmartPReP, Harvest Technologies, Plymouth,
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February 2011450 Lawall et alMass).40,46 A total BM-MNC number of between 1.5 and
10 	 109 cells was obtained using these techniques. This
corresponds to the cell count numbers described in the
meta-analysis by Fadini et al,32 in which the mean number
of mononuclear cells implanted or infused was 3.56 
2.81 	 109, and the mean CD34 cell count was 5.0 
1.48	 107, indicating that about 1.4% of transplanted cells
were CD34.
Both Ficoll and blood separator techniques require a
blood handling facility which is good clinical practice-
certified, usually either a specialized transfusion service or a
dedicated hematology unit, all of which are very labor
intensive. An additional sterile cell biology laboratory is
necessary if cells need to be expanded by further cultivation
steps.47,48 European Union-wide regulations for both Fi-
coll and separator techniques are tight, and special permis-
sion by the respective authorities is necessary. Attempting
to circumvent or overcome these obstacles, a single-step,
bedside, closed isolation system was developed recently.
This system is independent of specialized hospital subser-
vices without legal hurdles, and shortens total therapy time
from 8 to 10 hours to 1 hour. It also seems to be consid-
erably cheaper than separator or Ficoll-based tech-
niques,40,46 albeit having similar arteriogenic potency.
With the advent of simpler techniques, cell therapy may
thus gain impetus also in non-university hospitals that
currently treat the majority of patients with PAD.
Based on our ample experience with both the Ficoll
density gradient system and the bedside isolation method,
we strongly believe that simpler techniques will enhance
practicability of cell therapy. BM as compared to peripheral
blood seems to be the cell source of choice, a finding which
also holds true for cardiac applications, because withdrawal
of BM (usually between 100-250 mL) is fast (10 min-
utes), does not require general anesthesia but sedation
only, and yields reproducible cell numbers. In contrast,
PB-MNC collection requires expensive G-CSF injections
over 5 consecutive days and plasmapheresis for several
hours, these procedures being both time-consuming and
costly.
The Transplantation of Progenitor Cells and Regener-
ation Enhancement in Acute Myocardial Infarction (TOP-
CARE-AMI)49 and the Reinfusion of Enriched Progenitor
Cells and Infarct Remodelling in AMI (REPAIR-AMI)50
trials showed that Ficoll isolated BM-MNC was able to
improve cardiac function. This is in contrast to the findings
of the Autologous Mononuclear Bone Marrow Cells in
Acute AnteriorWallMyocardial Infarction (ASTAMI) trial,
which did not show an improvement of cardiac function
after intra-myocardial injection of BM-MNC isolated using
the Lymphoprep method.51 The conclusion drawn by See-
ger et al52 was that different diluents (saline vs heparin
plasma), and different buffer solutions and incubation me-
dia caused the reduced (about one-third) BM-MNC num-
ber and reduced function of the Lymphoprep isolated cells.
With respect to dosage, most trials aimed at using
MNC numbers comparable to those in the TACT study
(1.6	 109).30 There is no trial making direct comparisons of the degree of positive effects between different cell doses,
nd the only study trying to establish a correlation between
linical response and cell number had only 8 participants.53
yocardial Stem Cell Administration after Acute Myocar-
ial Infarction (MYSTAR) is the only published clinical trial
ith a positive correlation between the rate of improve-
ent of cardiac perfusion and the number of injected stem
ells in clinical cardiac stem cell therapy. It demonstrated
hat the only predictor for a reduction in infarct size was the
umber of intramyocardially injected cells.54
Tolerability and safety considerations. Long-term
afety has been questioned by a trial of intramuscular BM
ell therapy in which 1 of the 8 participating patients died
uddenly at 30 months after the procedure, 2 patients had
lcer worsening, and 1 patient had incompetent angiogen-
sis.55 This prompted other researchers to report the long-
erm status of their patients. In the meta-analysis by Fadini
t al,32 a total of 21 deaths (20 in the cell therapy group plus
in the G-CSF group) between 2 months and 3 years after
herapy of 761 patients treated are reported. No controlled
rial included reported mortality rates in the experimental
s the control groups. Safety data were described in 32 of
1 studies. BM aspiration was well tolerated, the most
requent adverse reaction being local pain, responsive to
onsteroidal anti-inflammatory drugs. Another less com-
on adverse event was mild anemia. G-CSF stimulation
as generally well tolerated, with prevalently minor side
ffects, including flu-like symptoms, myalgia, fever, and
one pain. Fadini et al,32 therefore, conclude that given the
xisting data, no worrying safety concerns exist, but that
ost studies included in the meta-analysis were not prop-
rly designed to assess safety in comparison with control
reatment, and that systematic reporting of adverse events
as rare.
The TACT late study was designed to assess the long-
erm safety and clinical outcomes of cell therapy by inves-
igating the mortality and leg amputation-free interval as
rimary end points.56 The median follow-up time for sur-
iving patients was 25 months, and the 3-year overall
urvival was 80% of patients with atherosclerotic PAD (11
f 74 patients died). This number increased to 100% in the
1 patients with TAO. The 3-year amputation-free rate was
0% in patients with PAD and 91% in patients with TAO.
he TACT late study also reported no cases of unwanted
eovascularization, no increase of the expected mortality,
nd no unwanted neovascularization. BONMOT-140 in-
luded 51 patients with impending major amputation due
o severe critical limb ischemia for BMC transplantation
nto the ischemic leg with a 3.2-year follow-up. Limb
alvage was 59% at 6 months and 53% at last follow-up.40
rom a clinical perspective, the most important finding was
hat patients with limb salvage improved from a mean
utherford category of 4.9 at baseline to 3.3 at 6 months.
hree severe periprocedural adverse events occurred (two
ases of anemia after 500 mL BM aspiration, one case of
arge bowel puncture) and resolved without sequelae, but
o unexpected long-term adverse events occurred. Based
n the data presented above, BM cell transplantation seems
s
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term side effects.
Future directions and ongoing randomized con-
trolled trials. A number of ongoing trials involving stem
cell therapy in the treatment of PAD and limb ischemia can
be found performing a database search of clinical trials at
NIH ClinicalTrials.gov. Recent search results (August
2010) yielded the 12 trials listed in the Table which also
lists further sub-specifications, such as condition to be
treated and intervention method, numbers enrolled, spon-
sor, and date of completion. Results of these trials will likely
Table. Ongoing randomized cell therapy trials in PAD an
NCT-ID
Acronym
(or other) Sponsor/location Condition
NCT-00377897 (OPTIPEC) Univ. of Paris 5;
AP-HP
CLI
NCT00392509 CLI-001 Aldagen CLI, PAD,
PVD
NCT00956332 (MGVS-MGA
002)
MultiGene
Vascular
Systems Ltd
PAD, CLI
NCT01065337 (HDZ-SBE-
2004)
Ruhr Univ.
Bochum
Diabetic
foot
NCT00468000 RESTORE-
CLI
Aastrom
Biosciences
PAD
NCT00523731 (TV-003,
ACPs-CLI)
TheraVitae Ltd PAD, CLI
NCT00951210 (1202-2) Pluristem Ltd PAD,
PVD,
CLI
NCT00919958 (PLX-PAD
1202-1)
Pluristem Ltd PAD,
PVD,
CLI
NCT00913900 SCRIPT-CLI Univ. of
Wisconsin,
Madison
CLI,
AOD,
VD
NCT00595257 (TriCell/CT/
IND-001)
Harvest
Technologies
AOD
NCT00616980 ACT34-CLI Baxter
Healthcare
PAD,
PVD,
CLI
NCT00434616 BONMOT-2 Franziskus
Hospital
Berlin
CLI
A-BMC-c, Autologous bone marrow cell concentrate; ABI, ankle-brachial
AOD, arterial occlusive disease; ASC, autologous stem cells; BMCs, bone m
CLI, critical limb ischemia, CPWH, complete primary wound healing;
improvement; i.m., intramuscular; inc., incidence; LPR, level of pain at rest;
life (as determined by questionnaire form); SLV, safety laboratory values; TcP
cells; VD, vascular disease.provide stronger efficacy data of cell therapy. Albeit trial itatus in the search database can be indicated as completed
full recruitment), patient treatment and control might still
e ongoing.
ONCLUSIONS
CLI represents the most severe manifestation of PAD
hat profoundly diminishes quality of life and global func-
ion and that is often associated with very high short-term
ortality. Prompt recognition, vascular specialty referral,
nd revascularization are the current standards of care.
evertheless, this care strategy is not always feasible, nor is
I
tervention
Patient
no. Outcome measure Phase
Completion
date
-MNC 20 ABI, TcPO2 I 12/09
H-br BM
lls vs MN-
MC
20 ABI, TcPO2,
QoL, LPR
I/II 12/08
tiGeneAngio 18 AE, improvem. of
CLI symptoms
I/II 01/26
, BMC 30 ABI, TcPO2,
amputation
status, CPWH
II 02/09
ologous
MC,
ectrolyte
lution (-C)
150 Safety of TRCs in
CLI patients,
amputation
status, ABI,
QoL, TcPO2
II 03/11
s or Vescell 6 Attenuation of
CLI, reduction
of amp. rate,
ulcer size
I 03/07
-PAD 12 AE, amp. rate,
inc. of death
I 12/10
-PAD IM
jection
15 AE, SLV, TG I 05/12
ologous
D133 cells
24 Death or amp.,
vascular
hemodynamics
and function
I 09/12
rtPReP2
MAC system
60 Avoid amp.,
measurem. of
HR
I/II 04/10
(CD34) 75 Ulcer healing,
funct.
improvem.,
limb salvage
I/II 10/09
MC-c vs
lacebo
? Reduction of
amp., induce
wound healing,
ABI, QoL,
TcPO2
II/III 03/10
; ACP, angiogenic cell precursors; AE, adverse events; amp., amputation;
stem cells; BM-MNCs, bone marrow mononuclear cells; -C, without cells;
, cell therapy; func., function; HR, hemodynamic response; improvem,
peripheral arterial disease; PVD, peripheral vascular disease; QoL, quality of
anscutaneous partial oxygen tension; TG, tumorigenesis; TRC, tissue repaird CL
In
BM
ALD
ce
B
Mul
TRC
Aut
B
el
so
ACP
PLX
PLX
in
Aut
C
Sma
B
ASC
A-B
p
index
arrow
CTH
PAD,t always effective. Evaluation of new pharmacological and
11
1
1
1
1
1
1
1
1
2
2
2
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literature supports that intramuscular BM cell administra-
tion is a relatively safe, feasible, and possibly effective ther-
apy for patients with PAD not susceptible to conventional
revascularization. This novel therapeutic option could also
soon be more widely available due to developments in the
private industry sector, which is in the process of con-
ducting promising second-generation trials. However,
there is a need for larger, placebo-controlled, random-
ized multicenter trials to confirm safety and efficacy of
this type of therapy, such as the ongoing BONMOT-
CLI41 (or BONMOT-2).
As an increasing number of clinical trial evidence sup-
ports routine use of stem cell therapy, more practical as-
pects of cell therapy will gain importance. Related to this, a
single-step, bedside, closed isolation system without the
need for specialized hospital subservices and without legal
hurdles is especially useful, particularly because it substan-
tially shortens total procedure time to 1 hour, and is con-
siderably less expensive than Ficoll-based techniques. This
may also enable non-university hospitals to use stem cell
therapy for treatment of their patients with PAD.
Ongoing trials may also shed light upon the open issue
still remaining to be resolved, such as selection of optimal
cell type, isolation method, cell number, and the role of
colony stimulating factors, route of administration, and
paracrine stimulation mechanisms.
In conclusion, autologous stem cell therapy seems to be
a promising tool for the treatment of ischemic peripheral
disease. Preliminary evidence confirms its safety, feasibility,
and effectiveness for several important end points, and a
number of large end point studies are ongoing to further
corroborate this evidence.
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